Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Operations (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Cash from Operations for 12 consecutive years, with 3342000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 32.72% year-over-year to 3342000.0, compared with a TTM value of 17228000.0 through Sep 2025, up 8.83%, and an annual FY2024 reading of 19356000.0, up 3.37% over the prior year.
  • Cash from Operations was 3342000.0 for Q3 2025 at Lisata Therapeutics, up from 3956000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2518000.0 in Q3 2024 and bottomed at 8196000.0 in Q1 2023.
  • Average Cash from Operations over 3 years is 4735272.73, with a median of 4184000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations increased 29.72% in 2024, then crashed 32.72% in 2025.
  • Year by year, Cash from Operations stood at 4069000.0 in 2023, then decreased by 11.28% to 4528000.0 in 2024, then rose by 26.19% to 3342000.0 in 2025.
  • Business Quant data shows Cash from Operations for LSTA at 3342000.0 in Q3 2025, 3956000.0 in Q2 2025, and 5402000.0 in Q1 2025.